Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic Programs NEW YORK, April 15, 2025 - PRISM MediaWire - PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc. (“Opus Genetics” or the “Company”) (Nasdaq: IRD), a clinical-stage gene therapy company developing treatments for inherited retinal diseases (IRDs) and broader ophthalmic conditions. Dr. George Magrath, Chief Executive Officer of...